Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics
GET POWR RATINGS... FREE!
VRCA Stock Price Chart Interactive Chart >
VRCA Price/Volume Stats
| Current price | $11.93 | 52-week high | $18.42 |
| Prev. close | $12.43 | 52-week low | $6.02 |
| Day low | $11.86 | Volume | 38,896 |
| Day high | $12.32 | Avg. volume | 107,232 |
| 50-day MA | $11.97 | Dividend yield | N/A |
| 200-day MA | $11.37 | Market Cap | 327.00M |
Verrica Pharmaceuticals Inc. (VRCA) Company Bio
Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.
Latest VRCA News From Around the Web
Below are the latest news stories about Verrica Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRCA as an investment opportunity.
RBC Capital: 3 Stocks to Buy With Over 50% Upside PotentialWhen investors are looking for fresh investment ideas, recent recommendations from Wall Street analysts can underscore compelling investment opportunities. This is where RBC Capital comes in. The investment firm has issued recommendations on 3 stocks, highlighting each based on its strong long-term growth prospects. While the firm’s analysts believe they are poised to surge at least 50% in the year ahead, we wanted to get the rest of the Street’s opinion. After using TipRanks’ database, we learned that each ticker has scored Buy ratings from other members of the analyst community as well. Verrica Pharmaceuticals (VRCA) We’ll start with Verrica Pharma, a therapeutics company working on treatments for dermatological conditions. |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Verrica Pharmaceuticals Inc. – VRCANEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the |
FDA Extends Review Period for Verrica Pharmaceuticals’ VP-102 Drug ApplicationVerrica Pharmaceuticals Inc. (VRCA) revealed that the U.S. Food and Drug Administration (FDA) extended the review period by three months for its New Drug Application (NDA) of VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease. The Prescription Drug User Fee Act (PDUFA) goal date has also been postponed by three months to September 23, 2021. (See Verrica Pharmaceuticals stock analysis on TipRanks) The extension has provided the agency some additional time to review the information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the company’s human factors study, the company said. |
Verrica's (VRCA) Skin Disease Candidate Approval Gets DelayedVerrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months. |
Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till SeptemberThe FDA has extended the review period for the marketing application for Verrica Pharmaceuticals Inc's (NASDAQ: VRCA ) VP-102 to treat molluscum contagiosum (molluscum). Now the Prescription … Full story available on Benzinga.com |
VRCA Price Returns
| 1-mo | 6.23% |
| 3-mo | -24.64% |
| 6-mo | 12.87% |
| 1-year | -6.14% |
| 3-year | -39.04% |
| 5-year | N/A |
| YTD | 3.65% |
| 2020 | -27.56% |
| 2019 | 94.97% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...